No abstract

The increase in parathyroid hormone (PTH) is related to a worse quality of bone mass. Bone densitometry, as an areal bone measurement, is not always able to assess bone microarchitecture. TBS (trabecular bone score) is a software that evaluates bone microarchitecture from the image of the lumbar spine obtained by bone densitometry. The articles have shown an excellent correlation of TBS with the risk of fragility fracture, especially in the individual who has primary hyperparathyroidism. We suggest that TBS may be an excellent method for assessing bone fragility in patients with hyperparathyroidism, especially if TBS is associated with bone densitometry.

Introduction Sex steroid hormones play a key role in bone health, however medical therapies for gender dysphoria lead to hormonal changes. Purpose Understanding the changes in bone mass and body composition is extremely important, because this treatment will be carried out over a long period of time. Methods In a prospective study, we included 19 trans women (male-to-female trans persons) before and after 1 year of therapy with estrogen and cyproterone acetate. Bone densitometry model Hologic-Discovery performed at baseline and after 6, 12 months of therapy. All participants signed the TCLE, project approved by CEP-CAAE: 36823220.6. 0000. 0062. Results Analysis of 19 transgender women with a mean age of 25 years +/- 10 years. LS-BMD (lumbar spine) at initial time (0m) 1,070±0,155g/cm2 and after 6 months (6m) 0,995±0,092g/cm2 and 12 months (12m) after 1,020±0,096 g/cm2, p=0,04; FN-BMD (Femur Neck) 0m= 1. 047±0.205g/cm2; 6m= 0.917±0.127g/cm2 and 12m= 0.909±0.120 g/cm2; p=0. 01. TH-BMD (Total Hip) 0m= 1.100±0.162 g/cm2; and 6m= 1. 021±0. 099g/cm2; 12m= 1. 015±0.119g/cm2; p=0. 02. About body composition: the percentage of body fat: 0m= 30.2±8. 0%, 6m= 31.3±7.9%; 12m= 33.2±10.2%; p=0.10; android/gynecoid ratio: 1. 00±0.26, 6m= 0.95±0.22; 12m= 1. 00±0.39; p=0,76, VAT mass (cm3) 411.8±252.1, 6m= 357.6±145.3, 12m= 395.5±167.7 p= 0,67 and Lean/Height2 (kg/m2) 0m= 17. 03±2.98, 6m= 15.94±1.8, 12m= 16.74±2.10; p=0.46 and Appen. Lean/Height2 (kg/m2) 7.89±1.67, 6m= 7.42±1.10 and 12m= 7.52±1. 01; p=0.90 Conclusion: In 1 year of hormone therapy with estrogen and cyproterone acetate, we found decrease in bone mass in the analyzed sites and no change in body fat and lean mass. Presentation: No date and time listed